Last reviewed · How we verify

NCT05445869

Severe OSA Study (SOS)

Terminated NA Last updated 18 April 2024
What this trial tests

NA trial testing ProSomnus® EVO Sleep and Snore Device in Obstructive Sleep Apnea in 35 participants. Terminated before completion.

Timeline
12 September 2022
Primary endpoint
15 February 2024
15 February 2024

Quick facts

Lead sponsorProSomnus Sleep Technologies
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment35
Start date12 September 2022
Primary completion15 February 2024
Estimated completion15 February 2024
Sites5 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

ProSomnus Sleep Technologies — full company profile →

Who can join

Adults 18 to 80, any sex, with Obstructive Sleep Apnea or Sleep Apnea. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective, multi-center, single-arm, open-label study evaluating the safety and effectiveness of therapy with the ProSomnus EVO Sleep and Snore Device in individuals with severe obstructive sleep apnea.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obstructive Sleep Apnea

Currently open trials in the same condition.

Other ProSomnus Sleep Technologies trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05445869.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing